A Study of JZP3507 for Recurrent Grade 2 or 3 Meningioma
This study is looking for people aged 18 or older with Grade 2 or 3 meningioma (a type of brain tumor) that has come back or hasn't responded to other treatments. You would take JZP3507 by mouth twice a day, three days a week, in 28-day cycles. The main goal is to see how well JZP3507 shrinks the tumor, as evaluated by independent experts. The study aims to enroll 30 participants, but the current recruitment status is unclear.
- Study design
- This is an interventional study with an estimated enrollment of 30 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would take oral JZP3507 twice daily, on 3 consecutive days per week in 28-day cycles. The duration of participation is not specified beyond the primary endpoint measurement.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your tumor response will be measured from the first dose until death, withdrawal of consent, or being lost to follow-up, for up to 40 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
At a glance
Conditions
Where it's being run
5 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall Response Rate (ORR) as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria and Evaluated by Blinded Independent Central Review (BICR)From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months.
ORR is the best response of confirmed complete response (CR), partial response (PR), or minor response (MR) during the study, as per RANO criteria